On a per-share basis, the
The results fell short of
The biotechnology company posted revenue of
Aurinia expects full-year revenue in the range of
Aurinia shares have decreased 63% since the beginning of the year. The stock has fallen 36% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from
Copyright by Automated Insights, Inc. All rights reserved., source